DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease.

Are dipeptidyl-peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors safe and effective at reducing cardiovascular mortality, all-cause mortality, and other cardiovascular outcomes (e.g., myocardial infarction, stroke, hospitalization from heart failure) in people with cardiovascular disease (CVD)? [ABSTRACT FROM AUTHOR]